India's Alivus Lifesciences posts higher third-quarter profit on API boost

Alivus Life Sciences

22/01/2026 08:42

Jan 22 (Reuters) - Indian drugmaker Alivus Life Sciences ALIV.NS, formerly called Glenmark Life Sciences, reported a higher third-quarter profit on Thursday, driven by strong demand in its mainstay active pharmaceutical ingredients (API) business.

The Mumbai-based company said its profit rose to 1.50 billion rupees ($16.4 million) in the three months ended December 31, from 1.37 billion rupees a year earlier.

Revenue from operations rose 4.8% to 6.73 billion rupees.

For further results highlights, click nFWN3YN06I.

KEY CONTEXT

Indian makers of APIs are seeing rising demand in key European and U.S. markets and are expected to benefit further as global drugmakers diversify supply chains away from China.

APIs are key elements added to drugs to produce desired health effects.

Alivus has more than 130 APIs in its portfolio, spanning therapeutic areas, including cardiovascular diseases, oncology and anti-infectives.

Peer Granules India GRAN.NS will report its December-quarter results on Friday.

PEER COMPARISON

Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Revenue growth (%)
Profit growth (%)
Mean rating*
# of analysts
Stock to price target**
Div yield (%)
Alivus Life Sciences Ltd
ALIV.NS
17.29
11.61
12.42
16.26
Strong Buy
4
0.72
0.58
Laurus Labs Ltd
LAUL.NS
63.15
30.84
16.38
37.46
Hold
14
1.16
0.15
Granules India Ltd
GRAN.NS
20.79
11.75
15.36
22.24
Buy
3
0.94
0.26
Divi's Laboratories Ltd
DIVI.NS
53.69
37.96
18.07
22.58
Hold
28
0.91
0.49

* Mean of analysts' ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** Ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT

OCTOBER TO DECEMBER STOCK PERFORMANCE

-- All data from LSEG

-- $1 = 91.6125 Indian rupees

Alivus Lifesciences' Q3 stock performance compared to peers https://reut.rs/4a31Pq9

(Reporting by Kashish Tandon in Bengaluru; Editing by Eileen Soreng)

((Kashish.Tandon@thomsonreuters.com; 8800437922;))